FDA
Drug Safety Communication: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (
dabigatran etexilate mesylate), FDA, December 7, 2011
Although Pradaxa, which is the brand name for
Dabigatran, is available on the market today, the
drug has come under significant scrutiny for its possibly dangerous side effects.